---
title: "Relief Therapeutics to get European patent for investigational drug RLF‑TD011"
date: "2025-02-11 12:01:59"
summary: "Relief Therapeutics (OTCQB:RLFTY) Tuesday said that the European Patent Office has issued a Decision to Grant for its patent application titled \"Therapeutic Uses of Oxidizing Hypotonic Acid Solutions.\" This patent will protect therapeutic applications of Relief's (OTCQB:RLFTY) proprietary, highly pure hypochlorous acid solutions, including its investigational drug RLF‑TD011 for the..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/158649166/image_158649166.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

* Relief Therapeutics ([OTCQB:RLFTY](https://seekingalpha.com/symbol/RLFTY "Relief Therapeutics Holding SA")) Tuesday said that the European Patent Office has issued a Decision to Grant for its patent application titled "Therapeutic Uses of Oxidizing Hypotonic Acid Solutions."
* This patent will protect therapeutic applications of Relief's ([OTCQB:RLFTY](https://seekingalpha.com/symbol/RLFTY "Relief Therapeutics Holding SA")) proprietary, highly pure hypochlorous acid solutions, including its investigational drug RLF‑TD011 for the treatment of wounds caused by epidermolysis bullosa in key European countries.
* The EPO is expected to issue the patent formally on February 26, 2025, under patent number EP 3993811.
* The patent will remain in effect until 2040, as anticipated by the Notice of Allowance received in October 2024. Corresponding patent applications are under review in other major markets, including the United States and China, [the company said.](https://seekingalpha.com/pr/19997520-relief-therapeutics-announces-european-patent-office-decision-to-grant-patent-for-rlf-td011 "the company said.")
* RLF-TD011 has previously received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of EB.

[seekalpha](https://seekingalpha.com/news/4405921-relief-therapeutics-to-get-european-patent-for-investigational-drug-rlftd011)
